Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis

Cortés Castan, Javier; Twelves, Chris

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Cortés Castan, Javier
dc.contributor.author	Twelves, Chris
dc.date.accessioned	2021-10-22T06:44:47Z
dc.date.available	2021-10-22T06:44:47Z
dc.date.issued	2020-07
dc.identifier.citation	Cortes J, Twelves C. Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis. Breast J. 2020 Jul;26(7):1347–51.
dc.identifier.issn	1524-4741
dc.identifier.uri	https://hdl.handle.net/11351/6441
dc.description	Advanced breast cancer; Eribulin; Overall survival
dc.description.abstract	In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 301) reports the influence of the number of prior chemotherapy regimens (0-6) on OS in patients with locally advanced/MBC randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).
dc.language.iso	eng
dc.publisher	Wiley
dc.relation.ispartofseries	Breast Journal;26(7)
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Mama - Càncer - Quimioteràpia
dc.subject	Mama - Càncer - Prognosi
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	Disease-Free Survival
dc.title	Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1111/tbj.13686
dc.subject.decs	neoplasias de la mama
dc.subject.decs	/farmacoterapia
dc.subject.decs	supervivencia sin enfermedad
dc.relation.publishversion	https://doi.org/10.1111/tbj.13686
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Twelves C] Leeds Institute of Medical Research at St James's, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, UK
dc.identifier.pmid	31782589
dc.identifier.wos	000499279600001
dc.rights.accessrights	info:eu-repo/semantics/openAccess